AstraZeneca sells rights to cholesterol drug Crestor to GrunenthalAstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. Crestor is a Share XAstraZeneca sells rights to cholesterol drug Crestor to Grunenthalhttps://pharmaphorum.com/news/astrazeneca-sells-rights-to-cholesterol-drug-crestor-to-grunenthal/
Moderna seeks COVID vaccine okay as data backs 94% efficacyModerna has said it will file for US, European and UK emergency approval of its coronavirus vaccine straight Share XModerna seeks COVID vaccine okay as data backs 94% efficacyhttps://pharmaphorum.com/news/moderna-seeks-covid-vaccine-okay-as-data-backs-94-efficacy/
UK appoints COVID-19 vaccine rollout minister as country preps for launchThe UK has appointed Nadhim Zahawi as vaccine rollout minister as the country prepares for a potential approval Share XUK appoints COVID-19 vaccine rollout minister as country preps for launchhttps://pharmaphorum.com/news/uk-appoints-vaccine-rollout-minister-as-country-preps-for-swift-approval/
EU fines Teva and Cephalon €60.5m for ‘pay for delay’ schemeThe European Union has fined Teva and its neurology unit Cephalon €60.5 million for an elaborate “pay for Share XEU fines Teva and Cephalon €60.5m for ‘pay for delay’ schemehttps://pharmaphorum.com/news/eu-fines-teva-and-cephalon-e60-5m-for-pay-for-delay-scheme/
Vertex gets EU okay to treat younger cystic fibrosis patientsA new EMA approval has expanded the use of Vertex Pharma’s exon-skipping cystic fibrosis therapy Symkevi to children Share XVertex gets EU okay to treat younger cystic fibrosis patientshttps://pharmaphorum.com/news/vertex-gets-eu-okay-to-treat-younger-cystic-fibrosis-patients/
UK’s Salient Bio launches robotic COVID-19 testing platformUK diagnostics firm Salient Bio has launched a robotics-driven COVID-19 mass testing platform after spinning out from Imperial Share XUK’s Salient Bio launches robotic COVID-19 testing platformhttps://pharmaphorum.com/news/uks-salient-launches-robotic-covid-19-testing-platform/
Brexit could hinder access to coronavirus vaccines, says pharma groupThe UK’s pharma industry trade body has warned that Brexit could derail the government’s efforts to get coronavirus Share XBrexit could hinder access to coronavirus vaccines, says pharma grouphttps://pharmaphorum.com/news/brexit-could-hinder-access-to-coronavirus-vaccines-says-pharma-group/
FDA approves Alnylam’s ultra-rare disease drug OxlumoThe FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), Share XFDA approves Alnylam’s ultra-rare disease drug Oxlumohttps://pharmaphorum.com/news/fda-approves-alynlams-ultra-rare-disease-drug-oxlumo/
Pfizer/BioNTech prep US COVID-19 vaccine launch after emergency filingPfizer and BioNTech have filed for emergency use of their COVID-19 vaccine candidate in the US, paving the Share XPfizer/BioNTech prep US COVID-19 vaccine launch after emergency filinghttps://pharmaphorum.com/news/pfizer-biontech-us-covid-19-vaccine-launch-emergency-filing/
